Oren Steen
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Journal: Diabetes, obesity & metabolism
Published: October 17, 2024
Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight.
Journal: Obesity (Silver Spring, Md.)
Published: June 25, 2024
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
Journal: Diabetes, obesity & metabolism
Published: June 20, 2024
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
Journal: The lancet. Diabetes & endocrinology
Published: August 31, 2023
Immunogenicity of the Novel Glucagon Analogue Dasiglucagon: Results of a Dedicated Immunogenicity Trial in Type 1 Diabetes.
Journal: Diabetes technology & therapeutics
Published: July 12, 2021
Goal achievement of HbA1c and LDL-cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT.
Journal: Diabetes, obesity & metabolism
Published: February 17, 2020
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.
Journal: Canadian journal of diabetes
Published: March 06, 2018
WITHDRAWN: The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
Journal: Canadian journal of diabetes
Published: July 19, 2016
The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
Journal: Canadian journal of diabetes
Published: July 19, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026